Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output
S Dupuis-Girod, I Ginon, JC Saurin, D Marion, E Guillot… - Jama, 2012 - jamanetwork.com
Context The only treatment available to restore normal cardiac output in patients with
hereditary hemorrhagic telangiectasia (HHT) and cardiac failure is liver transplant. Anti–
vascular endothelial growth factor treatments such as bevacizumab may be an effective
treatment. Objectives To test the efficacy of bevacizumab in reducing high cardiac output in
severe hepatic forms of HHT and to assess improvement in epistaxis duration and quality of
life. Design, Setting, and Patients Single-center, phase 2 trial with national recruitment from …
hereditary hemorrhagic telangiectasia (HHT) and cardiac failure is liver transplant. Anti–
vascular endothelial growth factor treatments such as bevacizumab may be an effective
treatment. Objectives To test the efficacy of bevacizumab in reducing high cardiac output in
severe hepatic forms of HHT and to assess improvement in epistaxis duration and quality of
life. Design, Setting, and Patients Single-center, phase 2 trial with national recruitment from …